Journal
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume 46, Issue 2, Pages 185-189Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jjco/hyv187
Keywords
non-small-cell lung cancer; gene fusion; biological markers; RUNX1; GLRX5
Categories
Funding
- JSPS KAKENHI [15K20917, 15K18440, 23390147, 23249045]
- Grants-in-Aid for Scientific Research [15K20917, 15K18440, 23249045, 23390147] Funding Source: KAKEN
Ask authors/readers for more resources
Stage IA non-small-cell lung cancer cases have been recognized as having a low risk of relapse; however, occasionally, relapse may occur. To predict clinical outcome in Stage IA non-small-cell lung cancer patients, we searched for chimeric transcripts that can be used as biomarkers and identified a novel chimeric transcript, RUNX1-GLRX5, comprising RUNX1, a transcription factor, and GLRX5. This chimera was detected in approximately half of the investigated Stage IA non-small-cell lung cancer patients (44/104 cases, 42.3%). Although there was no significant difference in the overall survival rate between RUNX1-GLRX5-positive and -negative cases (P = 0.088), a significantly lower relapse rate was observed in the RUNX1-GLRX5-positive cases (P = 0.039), indicating that this chimera can be used as a biomarker for good prognosis in Stage IA patients. Detection of the RUNX1-GLRX5 chimeric transcript may therefore be useful for the determination of a postoperative treatment plan for Stage IA non-small-cell lung cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available